Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903

A multicenter Eastern Cooperative Group (ECOG) phase 2 trial assessed whether adding prednisone to lenalidomide would improve previously reported responses in persons with myelofibrosis (MF). Forty-eight subjects with anemia (42 evaluable) received lenalidomide, 10 mg/d, with a 3-month low-dose pred...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Mesa, Ruben A., Yao, Xiaopan, Cripe, Larry D., Li, Chin Yang, Litzow, Mark, Paietta, Elisabeth, Rowe, Jacob M., Tefferi, Ayalew, Tallman, Martin S.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: American Society of Hematology 2010
Gaiak:
Clinical Trials and Observations
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC2996111/
https://ncbi.nlm.nih.gov/pubmed/20651074
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2010-05-287417
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak